Inhibrx (NASDAQ:INBX - Get Free Report) announced its earnings results on Monday. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.88) by ($0.21), Zacks reports. The firm had revenue of $0.10 million for the quarter.
Inhibrx Trading Down 1.1 %
Shares of Inhibrx stock opened at $13.94 on Tuesday. Inhibrx has a 12-month low of $10.80 and a 12-month high of $35.42. The firm's 50-day moving average price is $13.33 and its two-hundred day moving average price is $14.67.
Analyst Ratings Changes
Separately, JMP Securities reissued a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.
Get Our Latest Research Report on Inhibrx
Inhibrx Company Profile
(
Get Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
